Drugs effective in left HF (such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor–neprilysin inhibitors, sodium-glucose cotransporter-2 inhibitors, beta-blockers, or ivabradine) are not recommended in patients with PAH [1]. Here, SLC5A2 is linked to pulmonary arterial hypertension.